The first public firm will become the first public firm in the NASDAQ-Number

The Bionex gene laboratory corporation officially included a focus strategy on Wednesday, and becomes a focus of the focus list on a strategic asset and becomes a strategic asset.

The Wyoming-Indabaraled Tech Firmal Announcement Announcement Eleerum Stratega WhitePappe was issued, and he has released a pilot strategy to manage the corporate treasury.

“It remains a bitkoin Software Platform “firm wrote it WhitepaperPosted on Wednesday.

If the company has already purchased or occupied or occupied, he has not been explored to the treasury asset assets on the screen.

Biogeceus has not yet responded Cipher Request comment on these points.

Despite the Bionexus, Bithnoxus Bithkin’s adoption by the institution of Bustkin by institutional investors.

“Unlike Beitcoine, my memelines provide additional revenue flow. The firres said the controversy owners could have benefited from the passers,” said the firm, “said its cycling.

Biontum, as a financial entity of the ENTERYUM, “confirms its long-term potential of an ENIMEUM FINANCIAL SUPPORTANCE OF THE ENTHERUM OF THE BITHERUM FINANCIAL SUPPORT

The company also monhalins each year in the settlement transactions, the settlement, US dollar, USD, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC, USDC.

Bioenx Elereum’s WhitePaper in ahead of the strategy in front of Update the protocol of the pacraIt considers a “long-term long-term infrastructure for business”.

Although optimism, there is an update of PCR issues facing In the last weeks, it is its Sepoliane Test Network Network Next Roadblocks from the test phase from the previous pores.

Biones, primarily, works in Asia, and in Asia, in the Genomic Diagnosticist and chemical distribution through its Malaysian subsidiary.

Issuance of industrial chemicals for production and aerood space is 90% of its total income. It also developed blood analyzes for segment, which reflected 10% of its income from RNA.

But he seems to be facing his financial problems for all his prospects.

In December last year, the company obtained NASDAQ warning for non-compliance of $ 1 price rules.

It was given temporarily eliminated, which was given to the reconstruction of until May 1, 2025. To address this, the bioner plan to divide the negative stock until April 7, 2025.

The company’s ten-month income amounted to $ 5.88 million, which exceeded $ 5.88 million dollars, and its reserves decreased by $ 0.32, and in 61%, information The financial time will be displayed.

Edited by Sebastian SBank